Inflammatory Bowel Disease

PARIS, France, June 1, 2026 Abivax announced positive topline results from its pivotal Phase 3 ABTECT maintenance trial evaluating...

PARIS, France, May 22, 2026 Abivax announced new three-year interim data from Study 108 showing that obefazimod maintained durable...

SAN DIEGO, May 7, 2026 Halozyme Therapeutics, Inc. announced a major global collaboration and license agreement with GSK to...

SHANGHAI, China – May 8, 2026 Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that...

NORTH CHICAGO, Ill., May 5, 2026 AbbVie Inc. has presented extensive new data across its gastroenterology portfolio at the...

GHENT, Belgium, May 2, 2026 MRM Health announced the initiation of its Phase 2b STARFISH-UC clinical trial (NCT07296315) evaluating...

Austin, Texas, USA, April 21, 2026 In a significant regulatory milestone for gastrointestinal therapeutics, Cristcot HD LLC has announced...

WILMINGTON, Del., April 2, 2026 Earendil Labs, an AI-driven biotechnology company, has announced that the first patient has been...

CAMBRIDGE, MASSACHUSETTS, March 24, 2026 Quotient Therapeutics has announced a multi-year research collaboration with Merck & Co. to discover...

STOCKHOLM, Sweden, Feb. 21, 2026 — Johnson & Johnson announced new long-term findings from the QUASAR long-term extension study...